Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research

Trial Title: Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research

NCT ID: NCT05747157

Condition: B-cell Acute Lymphoblastic Leukemia

Conditions: Official terms:
Precursor Cell Lymphoblastic Leukemia-Lymphoma

Conditions: Keywords:
Meta10-19
CAR-T Cells Therapy
r/r B-ALL

Study type: Interventional

Study phase: Early Phase 1

Overall status: Recruiting

Study design:

Allocation: N/A

Intervention model: Sequential Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Drug
Intervention name: Metabolically Armed CD19 CAR-T cells
Description: Each subject receive metabolically armed CD19 CAR-T cells by intravenous infusion.
Arm group label: Administration of Metabolically Armed CD19 CAR-T cells

Other name: Meta10-19

Summary: A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia

Detailed description: This is a single arm , open-label study. This study is indicated for relapsed and/or refractory CD19+ B-cell Acute Lymphoblastic Leukemia . The selections of dose levels and the number of subjects are based on clinical trials of similar foreign products. 1. Main research objectives: To evaluate the safety and efficacy of metabolically armed CD19 CAR-T Cells in the treatment of r/r B-ALL. 2. Secondary research objectives: A. To evaluate the pharmacokinetic (PK) and pharmacodynamics(PD) characteristics of metabolically armed CD19 CAR-T Cells after infusion. B. To evaluate tumor remission after infusion of metabolically armed CD19 CAR-T Cells.

Criteria for eligibility:
Criteria:
Inclusion Criteria: 1. The patient or his/her guardian voluntarily signed the informed consent； 2. Patients with relapsed and refractory B-cell Acute Lymphoblastic Leukemia. Definition of relapsed or refractory B-ALL (meeting one of the following conditions): 1. 2 or more relapses; 2. Bone marrow relapsed after allo-HSCT and prepared to infuse Meta10-19 more than 6 months after allo-HSCT ; 3. CR not achieved after standardized chemotherapy; 4. Philadelphia-chromosome-positive (Ph+) patients who are ineffective or intolerant to first- and second-generation tyrosine kinase inhibitor (TKI) treatments, or who have contraindications to tyrosine kinase inhibitors; 5. The number of primordial cells (lymphoblast and prolymphocyte) in bone marrow is ≥ 5% 3. CD19 expression was positive by biopsy or flow cytometry (accept the results of this peripheral blood mononuclear cells collection or previous Class A tertiary hospital before this peripheral blood collection); 4. Expected survival time greater than 12 weeks 5. The baseline ECOG score was 0 or 1； 6. Organ function： 1. Kidney function: Serum creatinine ≤1.5 times ULN, or； The glomerular filtration rate (eGFR) estimated by MDRD formula was ≥60m/min/1.73m2；[eGFR=186×（age）-0.203×SCr-1.154（mg/dl），for females, the result was ×0.742]； 2. Liver function： ALT≤5 times ULN, and; Patients with total bilirubin ≤2.0mg/dl, except those with Gilbert-Meulengracht syndrome. Patients with Gilbert-.Meulengracht syndrome with total bilirubin ≤3.0 times ULN and direct bilirubin ≤1.5 times ULN were included. 3. Pulmonary function: ≤CTCAE grade 1 dyspnea and oxygen saturation of blood (SaO2) ≥91% in indoor air environment. 7. Hemodynamic stability was determined by echocardiography or multichannel radionuclide angiography (MUGA) and LVEF ≥45％; 8. Patients using the following drugs must meet the following conditions: 1. Steroid: Therapeutic doses of steroids must be discontinued 2 weeks prior to Meta10-19 infusion. However, physiological replacement doses of steroids are permitted, hydrocortisone or its equivalent < 6-12mg/mm2/ day； 2. Immunosuppressive agent: Any immunosuppressive drug must be stopped ≥4 weeks before the informed consent is signed; 3. Anti-proliferative therapy other than preconditioning chemotherapy is discontinued within 2 weeks prior to Meta10-19 infusion； 4. Treatment for CNS disease must be stopped 1 week before Meta10-19 infusion (e.g., intrathecal methotrexate) 9. The patient has recovered from the toxicity of the previous treatment, that is, the CTCAE toxicity grade is less than 1 (The exception is specific toxicity of grade 2 or less, such as hair loss, which the researchers have determined is not recoverable in a short period of time) is suitable for pretreatment chemotherapy and CAR-T cell therapy; 10. Women of childbearing age and all male patients must consent to use an effective contraception for at least 12 months after Meta10-19 infusion and until two consecutive PCR tests show no more CAR-T cells in vivo. Exclusion Criteria: 1. Patients with isolated extramedullary relapse; 2. Patients with confirmed diagnosis of Burkitt's lymphoma/ leukemia; 3. Patients who had received prophylaxis for CNS leukemia within 1 week prior to Meta10-19 infusion; 4. Patients with present or history of central nervous system diseases such as seizures disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement; 5. Patients with history of allogeneic hematopoietic stem cell transplantation (allo-HSCT) within 6 months prior to Meta10-19 infusion; 6. Patients who had received chemotherapy other than preconditioning chemotherapy within 2 weeks prior to Meta10-19 infusion ; 7. Patients who participated in other clinical trials within 30 days prior to enrollment; 8. Patients with active hepatitis B (defined as hepatitis B surface antigen positive or hepatitis B core antibody positive, concomitant hepatitis B virus DNA level > 1000 copies/ml) or hepatitis C (HCV RNA positive); 9. Patients with HIV antibody positive or treponema pallidum antibody positive; 10. Patients with uncontrolled acute life-threatening bacterial, viral or fungal infections (e.g. positive blood cultures ≤72 hours before Meta10-19 infusion) 11. Patients with unstable angina pectoris and/or myocardial infarction within 6 months prior to enrollment； 12. Patients with history of other malignancies, but the following conditions can be enrollment: 1. Adequately treated basal or squamous cell carcinoma (requiring adequate wound healing before signing informed consent); 2. Carcinoma in situ (DCIS) of cervical or breast cancer, which has been treated therapeutically, has shown no signs of recurrence for at least 3 years prior to the signing of the informed consent； 3. The primary malignancy has been completely resected and in complete remission for ≥5 years。 13. Women who are pregnant or breastfeeding (pregnancy tests for women of childbearing age are positive); 14. Patients with active neuroautoimmune or inflammatory conditions (e.g. Guillian-Barre syndrome, amyotrophic lateral sclerosis); 15. Other conditions that the investigator considered should not be enrolled in this clinical study, such as poor compliance.

Gender: All

Minimum age: 3 Years

Maximum age: 70 Years

Healthy volunteers: No

Locations:

Facility:
Name: Anhui Provincial Hospital

Address:
City: Hefei
Country: China

Status: Recruiting

Contact:
Last name: Xingbing Wang, PhD

Phone: +8613856007984
Email: wangxingbing@ustc.edu.cn

Investigator:
Last name: Xingbing Wang, PhD
Email: Principal Investigator

Start date: February 15, 2023

Completion date: May 15, 2025

Lead sponsor:
Agency: Anhui Provincial Hospital
Agency class: Other

Collaborator:
Agency: Leman Biotech Co., Ltd
Agency class: Other

Source: Anhui Provincial Hospital

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05747157